BEIJING, June 5, 2025 /PRNewswire/ — Tsingke Biotech recently participated in TIDES USA 2025, the leading international event for oligonucleotide and peptide therapeutics, held in San Diego from May 19 to 22. As a repeat exhibitor, Tsingke highlighted its integrated "The Great Gene Factory" model, offering precision synthesis solutions from early discovery to large-scale manufacturing.
During the exhibition, Tsingke showcased its core offerings including:
End-to-End synthesis tools, such as the Syn-HCY Series (12P/192P/768B), delivering high-throughput oligo production for CRISPR, IVD, and research needs GMP production system, featuring the Syn-HL12 synthesizer capable of 200 nmol to 12 mmol scale, equipped with real-time monitoring for UV, pH, and conductivity Application coverage across ASO/siRNA therapeutics, gene editing, mRNA vaccine templates, and diagnostic probes Over 300 chemical modifications and a robust raw material supply chain supporting batch-to-batch consistency
Visitors were particularly impressed by Tsingke’s automation capabilities and flexible modular equipment designed to support high-purity, long-chain, and highly modified oligonucleotide synthesis. The company’s ability to integrate reagents, instruments, and services into a unified platform drew significant attention from pharmaceutical and biotech partners.
Tsingke Biotech remains committed to empowering life sciences and therapeutic innovation by building a world-class platform for nucleic acid synthesis.
For inquiries or collaboration, please contact us at market@tsingke.com
Visit: www.tsingke.com
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
